Google
NRSNW — NEUROSENSE THERAPEUTICS LTD. WARRANT
NRSNW FAQ
What is NRSNW's ROE?
NEUROSENSE THERAPEUTICS LTD. WARRANT reports a Return on Equity (ROE) of 713.14%.
What is NRSNW's dividend yield?
NEUROSENSE THERAPEUTICS LTD. WARRANT offers a dividend yield of 0.00%.
What is NRSNW's Deepscope Quality Score?
Deepscope rates NRSNW's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NRSNW?
Deepscope's AI Timing Score for NRSNW is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
|
USD 0.18
Price
0.03
(23.93%)
Day Change
|
|
|---|
NRSNW, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.18 |
| PBV / Sector |
-3.75 / N/A
|
| Earning Per Share | -0.44 |
| PE / Sector |
N/A / N/A
|
| PEG or PE/Growth / Sector |
N/A / N/A
|
| Average 1M Daily Value |
366.828780000000
|
| Average 1W Daily Value |
663.689320000000
|
| Timing Factors |
|
42% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Building B, Herzliya, Israel, 4672562
Phone: 972 9 799 6183
Website: https://www.neurosense-tx.com
Sector: -
Description: NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
ME vs SECTOR
Click a bubble to view stock details · Bubble size represents market capitalization share
